CeleCor Therapeutics
0 followers
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto... Read more
Org chart
Robert S. Hillman
Co-Founder, President & CEO
Robert S. Hillman
Collapse
Barry S. Coller
Chair, Medical & SAB, Co-Founder
Marijo Gleeson
Chief Financial Officer
Peter Finn
Corporate Counsel
Oana Cociorva
Senior Director, Planning & Administration
